Invetech, a global leader in advanced therapies manufacturing solutions, has announced a strategic collaboration with AiCella, an AI-driven biotech startup, to revolutionize cell therapy production through the integration of artificial intelligence and custom automation technologies. The partnership was announced on June 27, 2025, and aims to address persistent challenges in cell therapy manufacturing while accelerating innovation across the industry.
Combining Automation Expertise with AI Innovation
The collaboration brings together Invetech's three decades of experience in end-to-end custom automation with AiCella's cutting-edge artificial intelligence platform. According to Andreas Knaack, President of Invetech, the partnership represents more than just a technological combination.
"This collaboration is about more than just combining technologies—it's about solving some of the most persistent challenges in cell therapy production," Knaack stated. "By integrating AiCella's predictive AI models with our proven technology platforms, we aim to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and ultimately accelerate the path to scalable, patient-ready therapies."
AI-Driven Process Optimization
AiCella's approach focuses on uncovering relationships between manufacturing processes and patient outcomes that traditional methods often miss. Geoffrey Stephens, PhD, CEO and Founder of AiCella, explained the company's strategic vision for the collaboration.
"Our goal at AiCella is to uncover the hidden relationships between process inputs and patient outcomes—insights that traditional methods often miss," Stephens said. "Through this collaboration with Invetech, we're embedding our AI models directly into the development and manufacturing lifecycle. This allows us to not only optimize process performance but also to generate data-driven hypotheses about which parameters most influence therapeutic efficacy—bringing us closer to truly personalized, responsive cell therapies."
Targeting the Cell Therapy Manufacturing Market
The partnership addresses the substantial $10B+ cell therapy manufacturing market through AiCella's Insights™ platform, which integrates real-world process and clinical data with advanced machine learning models. The platform is designed to help biopharma developers optimize manufacturing efficiency, reduce costs, and improve therapeutic outcomes.
AiCella's technology revolutionizes process development by seamlessly integrating real process and clinical data to maximize patient responses. The company's approach involves collecting data with strategic partners to enable researchers globally to bridge the gap between process development and clinical responses.
Industry Presence and Future Outlook
Both companies plan to showcase their joint capabilities at upcoming industry events throughout 2025, including Meeting on the Mesa in October. This collaboration represents a significant step toward integrating AI-driven insights into cell therapy manufacturing, potentially transforming how the industry approaches process development and optimization.
Invetech's proven modules, technology platforms, and custom automation solutions are designed to integrate seamlessly with existing processes, reducing time to market and supporting scalable, GMP-compliant manufacturing. The company has partnered with leaders in diagnostics, life sciences, and cell therapy for over three decades to co-create breakthrough solutions that transform ideas into market-ready technologies and therapies.
